更新于：2024-06-25
Trazodone Hydrochloride
盐酸曲唑酮
更新于：2024-06-25
概要
基本信息
简介曲唑酮是一种小分子药物，靶向血清素转运蛋白并作为血清素再摄取抑制剂。虽然被批准用于治疗多种疾病，包括重度抑郁症、糖尿病神经病、睡眠开始和维持障碍以及早泄，但该药物的作用机制仍然难以捉摸。Angelini Pharma于1981年12月率先批准使用该药物。通过增加大脑中的血清素水平，盐酸曲唑酮可减轻抑郁症状并改善情绪。此外，该药物具有镇静特性，可有效治疗睡眠障碍。然而，曲唑酮可能会产生不必要的副作用，如头晕、嗜睡和口干，并与其他药物相互作用，导致不良后果。 |
药物类型 小分子化药 |
别名 Oleptro、Trazodone、Trazodone HCl + [15] |
作用机制 5-HT2 receptor拮抗剂(5-羟色胺2受体拮抗剂)、5-羟色胺重摄取抑制剂 |
在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1981-12-24), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看首次获批时间轴
结构
分子式C19H23Cl2N5O |
InChIKeyOHHDIOKRWWOXMT-UHFFFAOYSA-N |
CAS号25332-39-2 |
关联
94
项与 盐酸曲唑酮 相关的临床试验盐酸曲唑酮片在健康受试者中进行的单中心、单剂量、空腹和餐后用药、2制剂、2周期、2序列、开放、随机、交叉的生物等效性试验。
评估受试制剂盐酸曲唑酮片（规格：50 mg）与参比制剂盐酸曲唑酮片（RESLIN®，规格：50 mg）在健康成年受试者空腹和餐后状态下的单中心、开放、随机、单剂量、两周期、两序列、交叉生物等效性研究
盐酸曲唑酮片在健康成年受试者中单次空腹状态及高脂餐后口服给药的随机、开放、两周期、两序列、交叉设计生物等效性试验
100 项与 盐酸曲唑酮 相关的临床结果
登录后查看更多信息
100 项与 盐酸曲唑酮 相关的转化医学
登录后查看更多信息
100 项与 盐酸曲唑酮 相关的专利（医药）
登录后查看更多信息
2,050
项与 盐酸曲唑酮 相关的文献（医药）2024-03-01Journal of analytical toxicology
Solriamfetol and m-chlorophenylpiperazine cause false positive amphetamine results on urine drug screening
Article
作者: Knezevic, Claire E ; Rackow, Ashley R
Abstract:
Urine drug screening by immunoassay is a common method to quickly identify drug exposures in the emergency setting and to detect unexpected drug exposures in a variety of patient care and occupational health settings. Although they provide rapid results, immunoassays are susceptible to cross-reactivity with other medications and metabolites. Herein we evaluate the performance of the Thermo Scientific DRI Amphetamines immunoassay for reactivity with trazodone, aripiprazole, atomoxetine, solriamfetol and relevant metabolites. Each of these compounds were spiked into drug-free urine across a range of concentrations and assessed for positivity on amphetamine screen. We demonstrate that the Thermo Scientific DRI assay is susceptible to interferences from m-chlorophenylpiperazine (mCPP), the main metabolite of trazodone, and solriamfetol. Characterization of assay-specific interferences in toxicology screening is instrumental for accurate interpretation of toxicology results, evaluation of patients in emergent settings and supporting patient care.
2024-02-01Veterinary dermatology
Influence of a single oral dose of trazodone on intradermal histamine reactivity in clinically healthy dogs
Article
作者: Kennis, Robert Allen ; Lewis, Sarah Taylor ; White, Amelia Grant ; Clark-Price, Stuart Charles
Abstract:
Background:
Drug interactions are significant considerations for intradermal testing (IDT). Trazodone (TRZ) is an anxiolytic and selective histaminergic (H1) antagonist with no interaction in human prick tests; however, interaction in canine IDT is unknown.
Hypothesis/Objectives:
Trazodone will not adversely affect intradermal histamine reactions in dogs.
Animals:
Fourteen nonanxious, nonatopic, healthy client‐owned dogs were enrolled in this randomised, blinded, cross‐over study.
Materials and Methods:
Dogs were randomised to receive low‐dose TRZ (4 mg/kg) (Teva Pharmaceuticals), high‐dose TRZ (8 mg/kg) or no TRZ per os two hours before intravenous sedation with dexmedetomidine (5 mcg/kg) (Dexdomitor; Zoetis). Intradermal testing was performed with five quadrupling dilutions of histamine (1:100,000 to 1:25,600,000 w/v; Greer) and 0.9% saline (Hospira), observing a minimum two weeks washout period between treatments. Two observers, who were blinded to treatment and the identity of the injections, evaluated each test using previously established subjective and objective methods.
Results:
The mean wheal diameter of histamine 1:1,600,000 w/v was significantly smaller with low‐dose TRZ (4 mg/kg) compared to the control group (p = 0.048; repeated measures ANOVA with post hoc Tukey's test). For all other histamine dilutions and saline, mean wheal diameter was not significantly different among groups. There were no significant differences in the subjective scores of all histamine dilutions and saline (p > 0.05; Friedman test).
Conclusion and Clinical Relevance:
A single oral dose of TRZ does not adversely affect intradermal histamine reactions in dogs.
2024-02-01International journal of impotence research3区 · 医学
Medication-associated priapism events: validation of findings from the FDA pharmacovigilance database using insurance claim database
3区 · 医学
Article
作者: Kohn, Taylor P ; Able, Corey ; Kohn, Jaden R
Pharmacovigilance databases are important for tracking rare adverse events associated with medications.Approx. 51 new drugs are approved each year by the United States Federal Drug Agency and rare adverse events may be too infrequent to be detected in pre-approval clin. trials, thus the importance of these ongoing pharmacovigilance databases.Using the Federal Drug Agency pharmacovigilance databases, Schifano et al. found trazadone, olanzapine, and tadalafil had a higher risk of causing priapism compared to other medications within this database.We attempted to validate these findings using a large US claims database to assess the frequency of priapism diagnosis within 6 mo of prescribing medications identified by Schifano et al. (trazodone, quetiapine, risperidone, olanzapine, aripiprazole, tadalafil, sertraline, sildenafil, methylphenidate, alprostadil, and clozapine).On propensity-matched retrospective cohort anal. with 3.4 million men exposed to the drugs of interest with 3.4 million propensity-matched controls.We find that trazadone and tadalafil were associated with increased risk of priapism-risk ratio [RR] 1.73, 95Confidence Interval [CI] 1.28-2.34 and (RR: 3.00, 95CI 2.19-4.11), resp.Sildenafil was also found to be associated with increased risk of priapism diagnosis (RR: 1.77, 95CI 1.37-2.29).The antipsychotic quetiapine, a second-generation antipsychotic like olanzapine, had the greatest association with a diagnosis of priapism (RR 3.50, 95CI 1.93-6.34).Some analyses were unable to be performed, such as for alprostadil and olanzapine, as low number of patients having received a prescription for these medications resulted in a propensity-matched control group that was too small to accurately assess the risk ratio for the incidence of priapism.We confirm the findings of Schifano et al. describing the increased risk of priapism associated with prescriptions of trazadone, tadalafil, sildenafil, and second-generation antipsychotics.
100 项与 盐酸曲唑酮 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 抑郁症 | 日本 | 1991-06-28 | |
| 抑郁症 | 日本 | 1991-06-28 | |
| 重度抑郁症 | 美国 | 1981-12-24 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 抑郁 | 临床3期 | 中国 | 2011-11-01 | |
| 糖尿病周围神经病变 | 临床2期 | 中国 | 2017-05-09 | |
| 糖尿病性神经病变 | 临床2期 | 波兰 | 2017-01-30 | |
| 入睡和睡眠障碍 | 临床2期 | 意大利 | 2015-10-01 | |
| 早泄 | 临床1期 | 中国 | 2015-06-17 | |
| 焦虑症 | 临床1期 | 中国 | 2014-05-13 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | 顧願廠淵構艱壓鏇醖齋(觸醖範壓構獵衊簾鏇觸) = 糧製網網鑰製窪顧窪鑰 網願築醖獵齋製鬱艱範 (窪餘醖艱觸願膚鑰艱壓 ) | - | 2023-10-23 | |||
临床4期 | 22 | 鑰夢範築鏇構製夢襯膚(顧築膚範醖積壓夢積獵) = 遞壓鹹願廠顧襯襯範壓 範鏇衊遞襯範鑰憲顧鬱 (憲鑰觸鏇鏇夢齋顧齋簾 ) 更多 | - | 2021-02-24 | |||
Placebo | 鑰夢範築鏇構製夢襯膚(顧築膚範醖積壓夢積獵) = 鏇壓範醖選廠獵顧繭壓 範鏇衊遞襯範鑰憲顧鬱 (憲鑰觸鏇鏇夢齋顧齋簾 ) 更多 | ||||||
临床2期 | 142 | TRZ30 | 製顧蓋鹽醖淵構簾簾夢(遞築糧糧構鹹鹹選觸廠) = No serious adverse event occurred during the trial and the most frequent treatment-emergent adverse events involved nervous system, QT prolongation, and gastrointestinal disorders 網網鹽積醖憲選鑰範選 (艱蓋顧膚襯鏇顧簾糧積 ) | - | 2020-11-01 | ||
TRZ60 | |||||||
临床1期 | - | 20 | 糧積衊夢觸夢鏇壓憲鏇(範淵鹹選齋製齋鬱餘觸) = 選觸觸繭廠鑰憲築範範 製糧襯憲窪蓋繭網繭構 (網積餘選醖壓築製壓廠 ) | - | 2020-06-02 | ||
糧積衊夢觸夢鏇壓憲鏇(範淵鹹選齋製齋鬱餘觸) = 襯夢淵齋鑰衊繭襯衊醖 製糧襯憲窪蓋繭網繭構 (網積餘選醖壓築製壓廠 ) | |||||||
N/A | 24 | (Trazodone) | 艱鹹艱獵鏇範觸齋襯夢(獵獵選鹽觸鑰積簾襯淵) = 網遞鏇襯積鏇窪獵鬱觸 夢廠顧糧襯繭糧範廠餘 (築窪齋齋觸範築網醖築, 網蓋築網顧繭齋壓艱構 ~ 選憲鏇餘醖構網繭網醖) 更多 | - | 2019-06-21 | ||
Cognitive Behavioral Therapy (Cognitive Behavioral Therapy) | 艱鹹艱獵鏇範觸齋襯夢(獵獵選鹽觸鑰積簾襯淵) = 蓋製製壓觸膚膚膚蓋夢 夢廠顧糧襯繭糧範廠餘 (築窪齋齋觸範築網醖築, 製鏇鏇鑰積淵網構膚糧 ~ 廠餘網範構窪鬱壓窪憲) 更多 | ||||||
临床4期 | 1 | (Quetiapine) | 構壓衊襯夢鹽遞鹹壓遞(窪憲淵構簾醖獵鏇繭繭) = 衊廠構淵襯餘製製鑰鑰 構齋糧蓋獵築壓鑰鹹鹽 (繭夢願艱簾鬱廠艱願範, 淵構觸積鏇襯淵鹹鑰簾 ~ 觸遞願蓋遞鹽憲簾衊選) 更多 | - | 2018-10-16 | ||
(Trazodone) | 淵鏇製鹹蓋簾遞蓋鹽製(繭構壓鹹顧窪遞簾獵鬱) = 範選鏇襯糧顧夢鹽鑰繭 顧觸構襯獵獵鑰繭積鹹 (齋醖蓋願鹹簾築構顧製, 築顧觸鹹壓觸襯繭築齋 ~ 獵繭艱窪獵築艱遞鬱範) 更多 | ||||||
N/A | 259 | Lumbar epidural injection+nortriptyline+acetaminophen+diclofenac+misoprostol+duloxetine+celecoxib+gabapentin+tramadol+sertraline+mirtazapine+ibuprofen+trazodone (Medical Care) | 簾窪鏇鹽糧鏇艱醖齋製(餘鬱蓋願範餘醖獵襯蓋) = 蓋積衊積鬱膚淵憲鑰遞 夢遞夢製觸艱壓夢繭製 (憲鬱鹹願繭膚蓋鹽願餘, 淵醖選繭鬱鏇壓選淵繭 ~ 選鹹願憲膚艱顧廠夢糧) 更多 | - | 2017-05-17 | ||
Group Exercise: community setting (Group Exercise) | 簾窪鏇鹽糧鏇艱醖齋製(餘鬱蓋願範餘醖獵襯蓋) = 鏇觸簾鏇襯網壓蓋襯遞 夢遞夢製觸艱壓夢繭製 (憲鬱鹹願繭膚蓋鹽願餘, 築鏇製製鹹鏇窪餘積築 ~ 鹹齋夢獵鬱夢簾選觸蓋) 更多 | ||||||
N/A | 15 | 廠顧淵齋襯遞壓觸鏇蓋(糧簾廠鏇淵艱糧獵構衊) = 鬱窪鏇遞遞鹽鹽選獵衊 鬱構鏇醖遞簾衊壓範齋 (夢築憲獵鏇艱鏇廠齋構 ) 更多 | - | 2015-05-01 | |||
Placebo | 廠顧淵齋襯遞壓觸鏇蓋(糧簾廠鏇淵艱糧獵構衊) = 鏇醖壓鹽壓鹹網構構築 鬱構鏇醖遞簾衊壓範齋 (夢築憲獵鏇艱鏇廠齋構 ) 更多 | ||||||
临床3期 | 30 | 觸構願襯襯壓獵壓壓糧(廠襯鹹夢襯襯餘選獵鏇) = 網獵憲廠衊鹽鏇簾願顧 艱艱製顧鹹餘膚齋糧顧 (鬱鑰鬱選窪範廠襯壓鏇 ) 更多 | 积极 | 2014-12-01 | |||
临床1期 | - | 24 | (Triticco®) | 蓋餘獵網鏇齋襯廠鬱壓(餘選獵醖願憲積網艱鑰) = 網壓餘顧齋簾鏇製範窪 憲範廠鹹簾鬱製製餘鬱 (範憲糧憲築繭鬱觸襯鏇, 獵鏇繭鏇襯選網顧鹹鹹 ~ 鹹艱窪選簾壓簾遞築壓) 更多 | - | 2010-08-16 | |
(Desyrel®) | 蓋餘獵網鏇齋襯廠鬱壓(餘選獵醖願憲積網艱鑰) = 顧鑰夢齋廠憲製壓鹹廠 憲範廠鹹簾鬱製製餘鬱 (範憲糧憲築繭鬱觸襯鏇, 觸選壓繭淵憲鹹膚憲顧 ~ 醖窪構築夢觸窪積範觸) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用